LOX Systemic Inhibitor

LOX Systemic Inhibitor - myelofibrosis and pancreatic cancer

Pharmaxis has developed an oral drug inhibiting all lysyl oxidase family members. The compound has shown significant reductions in fibrosis in in-vivo models of kidney fibrosis, lung fibrosis, myelofibrosis and pancreatic cancer. Whereas the Pharmaxis selective LOXL2 inhibitors are suited to chronic fibrotic conditions such as IPF and NASH, this all-encompassing LOX inhibitor is well positioned for the treatment of severe fibrosis as well as cancer with prominent stroma (connective tissue) or fibrotic metastatic niches. Pharmaxis plans to initially develop the compound for pancreatic cancer.

Pharmaxis is collaborating with Garvan Institute of Medical Research to investigate the therapeutic potential of LOX inhibition in pancreatic cancer.

A Phase 1 clinical trial in healthy volunteers commence in February 2019 and reported in April 2020. The Phase 1 trial demonstrated a well-tolerated drug that effectively inhibits all enzymes in the lysyl oxidase family that are involved in fibrosis. Long term toxicity studies completed clearing the way for 6-month phase 2 studies in several cancers with the opportunity to demonstrate disease modifying efficacy. The pre-clinical program, regulatory advice and opinion from leading clinicians supports progression into a phase 2 study of myelofibrosis, a rare bone cancer with high unmet need and significant market opportunity. The phase 2 study is planned to commence recruitment in Q4 2020.

 Watch a presentation on Fibrosis, LOX and Cancer by Dr Thomas R. Cox, Leader of the Matrix and Metastasis Team, Garvan Institute of Medical Research.

Watch a presentation on the Pharmaxis LOX program by Pharmaxis Head of Drug Discovery - Dr Wolfgang Jarolimek.

Access Pharmaxis Publications and Posters on LOX inhibitors

Skip to

Stromal tumours